AAS Creates Viable Protein Expression Opportunities for Global Pharmaceutical Company
Complete the form below to unlock access to ALL audio articles.
Ajinomoto AminoScience LLC has announced the availability of a case study profiling how one global pharmaceutical company relied on the Corynex™ Recombinant Protein Expression System to simplify the development of recombinant proteins.
AAS began working with this top tier pharmaceutical company almost two years ago. The firm had difficulty expressing some of its therapeutic proteins via traditional e-coli and yeast-based expression systems and was interested in Ajinomoto’s proprietary Corynex™ Expression System. This system uses the gram-positive Corynebacterium glutamicum to reduce purification steps, lower costs, and increase yield.
Based on initial successes, the company chose to team with Ajinomoto to further evaluate the potential suitability of Corynex™ to streamline the development and manufacture of a number of recombinant proteins. Ajinomoto was tasked with expressing any viable level of sixteen selected proteins several of which had prior expression levels ranging from less than 1 mg to 20 mg per liter.
Compared to e-coli and yeast-based expression systems, the bacterial-based Corynex™ expression system secretes correctly-folded, active proteins directly into the growth media with minimal host cell protein secretion and no endotoxins. By secreting active proteins directly into the growth media, Corynex™ eliminates the need for extensive downstream processing and additional refolding steps, which often result in 50% to 80% losses in target proteins.
Preliminary results show that with the development of protease deficient strains, Ajinomoto successfully expressed over 50% of the proteins within the study. This high success rate showcases the market potential for the Corynebacterium glutamicum expression method - especially with proteins that traditional expression systems have failed to express to viable levels.
The pharmaceutical company is now able to capitalize on the previous investments made in researching and developing these proteins by moving them along the development pipeline (as opposed to abandoning them).
